Early Detection of Endometrial/Ovarian Cancer and Hereditary Predisposition of These Cancers

NARecruitingINTERVENTIONAL
Enrollment

5,600

Participants

Timeline

Start Date

May 10, 2021

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2028

Conditions
Diagnoses Disease
Interventions
DIAGNOSTIC_TEST

DOvEEgene test

Women participating in the study will undergo a genomic uterine pap test, DOvEEgene test, for the screening of ovarian and endometrial cancers. Clinical tests will also be administered as a comparator (CA-125 blood test and TVUS).

Trial Locations (2)

H4A 3J1

RECRUITING

McGill University Health Centre, Royal Victoria Hospital, Montreal

H4A 3K6

RECRUITING

Queen Elizabeth Health Complex, Montreal

All Listed Sponsors
collaborator

Genome Canada

OTHER

collaborator

Genome Quebec

OTHER

collaborator

Research Institute of the McGill University Health Center

UNKNOWN

collaborator

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

lead

McGill University

OTHER